Biogen, a biotechnology company specializing in therapies for neurodegenerative diseases, and certain of the company’s executives were hit with a securities class action Monday in Massachusetts District Court. The lawsuit, brought by Block & Leviton, accuses the defendants of engaging in back-channel meetings with Billy Dunn, Office of Neuroscience chief for the Food and Drug Administration, in an effort to gain approval for Aduhelm, a drug meant to treat Alzheimer’s disease that had already failed to obtain approval. The complaint asserts that these meetings are now being investigated by the federal government. Counsel have not yet appeared for the defendants. The case is 1:22-cv-10200, Oklahoma Firefighters Pension and Retirement System v. Biogen Inc. et al.

This suit was surfaced by Law.com Radar, a source for high-speed legal news and litigation updates personalized to your practice. Law.com Radar publishes daily updates on just-filed federal cases like this one. Click here to get started and be first to know about new suits in your region, practice area or client sector.